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LETTERS TO THE EDITOR
Cyclooxygenase-2 in
Myocardial Ischemia: Is It Really a Friend?
We read with interest the elegant experimental study performed by
Shinmura et al. (1) and published in the Journal showing that
cyclooxygenase-2 (COX-2) inhibition prevents delayed ischemic
preconditioning and, in particular, reduction in postischemic
stunning. However, we believe it is unlikely that their experimental
findings have relevant clinical implications, as repeatedly suggested
by the investigators. Ischemic preconditioning has been shown to
reduce infarct size and myocardial stunning. However, the assess-
ment of infarct size is probably more complex than believed a few
years ago. Indeed, the majority of myocardiocytes are lost through
apoptosis (2,3), which is not assessed by standard techniques,
rather than through necrosis as previously thought. Therefore,
if assessment of infarct size is based solely on enzyme leakage
and/or on the extent of necrosis and fibrosis at pathology it does
not reflect total effective myocardiocyte loss. Notably, classic
studies on the effects of preconditioning on infarct size did not
take into account cell apoptosis, which might even be enhanced by
early or late ischemic preconditioning (2,4). Moreover, ischemic
preconditioning-induced reduction in stunning does not necessar-
ily have to be considered beneficial. The ischemic cell undergoes
both short- and long-term modifications to confront hypoxia, in a
delicate balance between survival and death (5,6). Stunning and
hibernation are natural responses to ischemia and are probably part
of the cellular mechanisms of adaptation aimed toward pro-
grammed cell survival after ischemia (5,6), whereas prolonged
ischemia (either with or without reperfusion) causes cell death.
Finally, and most importantly, recent data indicate that COX-2
is a mediator of ischemic damage. Takadera et al. (7) have shown
that COX-2 plays a key role in central nervous system apoptosis.
We have recently found that COX-2 expression in recent myo-
cardial infarction (MI) is associated with higher apoptotic rates (8);
Saito et al. (9,10), using an experimental model of MI, have
reported beneficial effects, in terms of postinfarction dysfunction,
of COX-2 inhibitors, and just recently high-dose aspirin was
found to protect myocardiocytes from apoptosis (11). Of note, in
a different experimental setting, Zhang et al. (12) found an increase
of COX-2 activity in genetically engineered animals prone to heart
failure, and, most interestingly, they describe beneficial effects of
selective COX-2 inhibition.
In conclusion, though COX-2 may provide a friendly protection
to ischemic myocardiocytes, as suggested by Shinmura and col-
leagues (1), evidence is still too scant to scientifically discard its
potential role as a foe leading to unfavorable outcomes in the
process of cardiac adaptation to ischemia. The present study by
Shinmura et al. (1) convincingly shows that COX-2 plays an active
role in myocardial response to ischemia and that inhibition of
COX-2 significantly affects the course of events after ischemic
insults. Whether the effect of COX-2 is beneficial or deleterious in
the clinical setting cannot be drawn from current data. Thus, the
statement that COX-2 inhibitors should be used with caution
because they may deprive the heart of its innate defensive response
is completely speculative to date as further studies are needed, and
COX-2 may ultimately be found to be more a “foe” than a “friend.”
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REPLY
We welcome the chance to reply to the letter of Dr. Abbate and
colleagues, as this gives us an opportunity to rectify a number of
common misconceptions. First, the assertion by Dr. Abbate and
colleagues that (following myocardial ischemia/reperfusion) “the
majority of myocardiocytes are lost through apoptosis” is not
supported by any evidence. Whereas apoptosis does occur after
acute myocardial ischemia and reperfusion (1), the quantitative
aspects of this process remain controversial and, at best, specula-
tive. Regardless, measurements of infarct size at 72 h after
reperfusion (as done by Shinmura et al. [2]) would include both
necrotic and apoptotic cell death. It is also incorrect to state that
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apoptosis might be enhanced by late preconditioning—again, no
evidence exists to support this assertion. On the contrary, late
preconditioning produces a marked reduction in infarct size (3).
There is also no evidence to support the suggestion by Dr. Abbate
and colleagues that reducing stunning is not beneficial; 20 years of
research have shown that myocardial stunning is an unnecessary
manifestation of reperfusion injury, which can be minimized
without adverse consequences (4). The antistunning effects of late
preconditioning (3) are associated with sustained improvement in
left ventricular (LV) function (5).
Similarly, the statement by Dr. Abbate and colleagues that
“COX-2 [cyclooxygenase-2] is a mediator of ischemic damage” is
not supported by the available evidence. The study by Takadera et
al. (6) dealt with PGE2 (rather than COX-2 per se) and examined
brain injury rather than cardiac injury. Apparently the abstract
cited by Dr. Abbate and colleagues (which is not available at the
time of this writing) showed an association between COX-2
expression and apoptosis; this association does not in any way
indicate a cause-and-effect relationship. Saito et al. (7) assessed LV
function (not infarct size) at four weeks after permanent occlusion
(not after transient occlusion followed by reperfusion). Their study
examined the role of COX-2 in LV remodeling, which is com-
pletely different from the role of COX-2 in limiting acute
ischemia/reperfusion injury; the two issues should not be confused.
The second study by Saito et al. (8) also examined a permanent
coronary occlusion (without reperfusion) and did not measure
infarct size as a percent of the risk region. Contrary to the
statements by Dr. Abbate and colleagues, considerable evidence
indicates that COX-2 by-products (particularly prostacyclin) exert
antiapoptotic actions (9). The abstract by Iwai-Kanai et al. (10)
examined apoptosis induced in vitro by isoproterenol or H2O2 (not
by ischemia) in neonatal (not adult) cardiac myocytes. There is no
evidence that aspirin acted by inhibiting COX-2 or that the model
used in that study (10) has anything to do with myocardial
ischemia/reperfusion. Although COX-2 has been reported to
mediate apoptosis in Gh transgenic mice (11), this is not a setting
relevant to myocardial ischemia/reperfusion injury, and the inves-
tigators indicated that the actions of COX-2 are complex (11).
In August 2000, we demonstrated, for the first time, that
COX-2 is a cardioprotective protein that alleviates both myocar-
dial stunning and infarction (2). We have subsequently reviewed
the mounting evidence for a protective role of COX-2 (9). Three
years have passed and increasing evidence supports our hypothesis.
Cyclooxygenase-2 protects isolated myocytes from oxidative stress
(12), and COX-2 inhibitors aggravate doxorubicin-mediated in-
jury (13). Targeted disruption of the COX-2 gene results in
myocardial fibrosis (14). Myocardial ischemia/reperfusion injury is
exacerbated in COX-2 null mice (15), implying that constitutively
expressed COX-2 is cardioprotective. Moreover, PGI2 is a potent
cytoprotective prostanoid (9), and COX-2 has been found to be
the major source of systemic biosynthesis of PGI2 in healthy
volunteers (16) and in patients with atherosclerosis (17).
As elaborated elsewhere (9), the concept that COX-2 is
deleterious during acute myocardial ischemia is a common mis-
conception. We propose that the biological effects of COX-2 may
differ depending on the cellular type(s) where it is expressed (e.g.,
vascular wall vs. cardiac myocytes), the pathophysiological setting,
and the ability of cells to metabolize COX-2-derived PGH2 into
cytoprotective prostanoids.
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